We are live on
!
Find out more
NTC
North Tide Capital Portfolio holdings
AUM
$469M
1-Year Est. Return
6.57%
This Fund
S&P 500
This Quarter
Est. Return
+2.03%
1 Year Est. Return
+6.57%
3 Year Est. Return
+14.81%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$469M
AUM Growth
+$19.5M
(+4.3%)
Cap. Flow
+$13.3M
Cap. Flow
% of AUM
2.84%
Top 10 Holdings %
Top 10 Hldgs %
91.11%
Holding
16
New
4
Increased
5
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$54.6M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$21.8M |
| 3 |
CVS Health
CVS
|
+$19.8M |
| 4 |
IVC
Invacare Corporation
IVC
|
+$14.6M |
| 5 |
SVU
SUPERVALU Inc.
SVU
|
+$12.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$67.8M |
| 2 |
Gilead Sciences
GILD
|
+$38.2M |
| 3 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$16.1M |
| 4 |
SEM
Select Medical
SEM
|
+$8.57M |
| 5 |
Option Care Health
OPCH
|
+$8.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SEM
1
DELISTED
Select Medical
SEM
| $86.4M | 18.43% |
8,352,000
-928,000
| -10% | -$8.57M |
|
|
2
McKesson
MCK
$98.5B
| $76.8M | 16.38% |
500,000
+350,000
| +233% | +$54.6M |
|
|
SVU
3
DELISTED
SUPERVALU Inc.
SVU
| $43.5M | 9.28% |
2,000,001
+571,430
| +40% | +$12.7M |
|
4
Viatris
VTRS
$20.1B
| $42.4M | 9.03% |
1,350,000
+350,000
| +35% | +$11.9M |
|
|
5
Gilead Sciences
GILD
$167B
| $40.5M | 8.64% |
500,000
-500,000
| -50% | -$38.2M |
|
|
ENDP
6
DELISTED
Endo International plc
ENDP
| $34.3M | 7.31% |
4,000,000
+1,000,000
| +33% | +$9.63M |
|
|
TVTY
7
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $30.6M | 6.53% |
750,000
-1,750,000
| -70% | -$67.8M |
|
8
Perrigo
PRGO
$1.48B
| $25.4M | 5.42% |
300,000
| – | – |
|
9
Tenet Healthcare
THC
$16.8B
| $25.2M | 5.38% |
1,534,200
+534,200
| +53% | +$9.06M |
|
|
ESRX
10
DELISTED
Express Scripts Holding Company
ESRX
| $22.2M | 4.73% |
+350,000
| New | +$21.8M |
|
|
11
CVS Health
CVS
$137B
| $20.3M | 4.34% |
+250,000
| New | +$19.8M |
|
|
IVC
12
DELISTED
Invacare Corporation
IVC
| $16.1M | 3.44% |
+1,023,000
| New | +$14.6M |
|
13
Pacific Biosciences
PACB
$447M
| $5.25M | 1.12% |
+1,000,000
| New | +$4.3M |
|
|
14
Option Care Health
OPCH
$3.41B
| – | – |
-750,000
| Closed | -$8.14M |
|
|
IPXL
15
DELISTED
Impax Laboratories, Inc.
IPXL
| – | – |
-1,000,000
| Closed | -$16.1M |
|
|
VVUS
16
DELISTED
Vivus Inc
VVUS
| – | – |
-500,000
| Closed | -$6.1M |
|
Similar funds
SD
DG
NBC
JWM
JPCCM
MCL
GIIO
FC
North Tide Capital's Q3 2017 Portfolio in Review
As of Q3 2017, North Tide Capital held 16 positions worth $469M, up 4.3% from $449M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
North Tide Capital's Q3 2017 filing shows 4 new, 5 increased, 3 reduced and 3 closed positions. Its largest new stake was Express Scripts Holding Company: 350,000 shares worth $22.2M. The largest sale was Tivity Health, Inc. Common Stock, an estimated $67.8M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier.
- North Tide Capital's largest Q3 2017 buy was Express Scripts Holding Company: 350,000 shares worth $22.2M.
- North Tide Capital added most to McKesson in Q3 2017, an estimated $54.6M increase.
- North Tide Capital's biggest Q3 2017 reduction was Tivity Health, Inc. Common Stock, cutting an estimated $67.8M.
- North Tide Capital fully exited Impax Laboratories, Inc. in Q3 2017, selling an estimated $16.1M.
- North Tide Capital's ten largest holdings make up 91% of its $469M portfolio in Q3 2017.
- North Tide Capital opened 4 new positions and closed 3 in Q3 2017.
- North Tide Capital's portfolio value rose 4.3% quarter-over-quarter to $469M.
Based on North Tide Capital's 13F filing for Q3 2017, filed 14 Nov 2017.